{
  "meta": {
    "title": "Neonatal_Hyperbilirubinemia",
    "url": "https://brainandscalpel.vercel.app/neonatal-hyperbilirubinemia-ed6f97b1.html",
    "scrapedAt": "2025-11-29T18:33:18.254Z"
  },
  "questions": [
    {
      "id": 15146,
      "choices": [
        {
          "id": 60544,
          "text": "<p><span style=\"font-size:11.0pt;\">Crigler-Najjar Syndrome Type I</span></p>"
        },
        {
          "id": 60545,
          "text": "<p><span style=\"font-size:11.0pt;\">Gilbert Syndrome</span></p>"
        },
        {
          "id": 60546,
          "text": "<p><span style=\"font-size:11.0pt;\">Dubin-Johnson Syndrome</span></p>"
        },
        {
          "id": 60547,
          "text": "<p><span style=\"font-size:11.0pt;\">Rotor Syndrome</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 17-year-old boy is found to have intermittent jaundice, especially during periods of stress or fasting. He is otherwise healthy, and liver function tests are normal except for mildly elevated unconjugated bilirubin. There is no evidence of hemolysis. What is the most likely diagnosis?</span></p>",
      "unique_key": "Q2250028",
      "question_audio": null,
      "question_video": null,
      "map_id": 32624,
      "difficulty_level": "intermediate",
      "subjects_id": [
        13
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans: B. Gilbert Syndrome</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Mild, unconjugated hyperbilirubinemia in healthy adolescents during stress or fasting due to reduced UGT1A1 activity.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Crigler-Najjar Syndrome Type I: </strong>Severe unconjugated hyperbilirubinemia in neonates due to complete absence of UGT enzyme; can cause kernicterus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;C. Dubin-Johnson Syndrome: </strong>Conjugated hyperbilirubinemia with a black-pigmented liver; due to defective bilirubin excretion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D. Rotor Syndrome: </strong>Also causes conjugated hyperbilirubinemia, but liver color is normal</span><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Remember the mnemonic for unconjugated hyperbilirubinemia is CNG - GAS&nbsp;</strong></span><br><span style=\"font-size:12.0pt;\"><strong>C: C</strong>rigler najjar syndrome&nbsp;</span><br><span style=\"font-size:12.0pt;\"><strong>G: </strong>Gilbert syndrome&nbsp;</span><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref- OP Ghai 9th Edition Page No- 312.</strong></span></p>",
      "correct_choice_id": 60545,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15150,
      "choices": [
        {
          "id": 60560,
          "text": "<p><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recommend cessation of breast-feeding for 48 hours and supplement with formula.</span></span></p>"
        },
        {
          "id": 60561,
          "text": "<p><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start phototherapy.</span></span></p>"
        },
        {
          "id": 60562,
          "text": "<p><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wait 6 hours and retest the serum bilirubin level.</span></span></p>"
        },
        {
          "id": 60563,
          "text": "<p><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start an exchange transfusion.</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A mother brought her 30-hour-old newborn to the pediatric clinic due to the development of jaundice, which is noticeable on the infant&#39;s face and chest. The infant is breastfeeding well and appears healthy on examination. Laboratory tests reveal a total bilirubin level of 17 mg/dL. Considering the infant&#39;s age, clinical presentation, and bilirubin level, what is the most appropriate next step in management?</span></span></span></p>",
      "unique_key": "Q4601778",
      "question_audio": null,
      "question_video": null,
      "map_id": 32626,
      "difficulty_level": "beginner",
      "subjects_id": [
        13
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Start phototherapy.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Although the <strong>etiology of hyperbilirubinemia </strong>must be <strong>investigated</strong>, <strong>phototherapy </strong>should be <strong>started based on the increased levels </strong>of <strong>bilirubin</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">For <strong>full-term infants without hemolysis</strong>, <strong>phototherapy </strong>is <strong>initiated at the following bilirubin levels</strong>: <strong>16-18 mg/dL </strong>at an age of <strong>24 to 48 hours.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>18-20 mg/dL </strong>at <strong>49 to 72 hours</strong>; and </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>more than </strong>or <strong>equal to 20 mg/dL at 72 hours </strong>or more.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phototherapy&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">is often <strong>used to treat unconjugated hyperbilirubinemia</strong>, with&nbsp;</span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">the <strong>unclothed infant placed under a bank of lights</strong>, the <strong>eyes shielded</strong>, and <strong>hydration&nbsp;</strong></span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>maintained</strong>. The <strong>blue-green light of wavelength 460-490 nm </strong>changes the <strong>skin&rsquo;s bilirubin </strong>into a <strong>water-soluble polar compound </strong>called <strong>Lumirubin </strong>which can be <strong>excreted from the body</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Cessation of breastfeeding:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is <strong>not recommended as a first-line intervention for jaundice</strong>. Breastfeeding should be encouraged to promote hydration and bowel movements, which can help reduce bilirubin levels.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Wait and retest:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Given the <strong>high bilirubin level </strong>for the <strong>infant&#39;s age</strong>, <strong>waiting without intervention </strong>could <strong>put the infant at risk </strong>for <strong>developing bilirubin encephalopathy</strong>. Immediate intervention is warranted.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Exchange transfusion:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is <strong>reserved for critically high bilirubin levels </strong>or when <strong>bilirubin levels do not respond to intensive phototherapy</strong>, especially if signs of acute bilirubin encephalopathy are present. Given the current bilirubin level and the age of the infant, phototherapy is the most appropriate initial step.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Physiological jaundice </strong>represents <strong>physiological immaturity of the neonates </strong>to <strong>handle increased bilirubin production</strong>.&nbsp; <strong>Visible jaundice </strong>usually <strong>appears between 24-72 hr of age</strong>. <strong>Total serum bilirubin </strong>(TSB) level usually <strong>peaks by 3 days of age </strong>and then <strong>falls in term neonates</strong>. <strong>TSB levels </strong>are <strong>below the designated cut-offs for phototherapy</strong>. It does not require any treatment.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pathological jaundice </strong>- </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>TSB levels </strong>have been <strong>arbitrarily defined as pathological if it exceeds 5 mg/ dl on first day</strong>, <strong>10 mg/dl on second day</strong>, or <strong>15 mg/ dl thereafter in term babies</strong>. Such jaundice warrants investigation for the cause and therapeutic intervention such as phototherapy. Appearance of jaundice within 24 hr, TSB levels above the expected normal range, presence of clinical jaundice beyond 3 weeks and conjugated bilirubin (dark urine staining the nappy) would be categorized under this category.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">-</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>OP Ghai 9<sup>th</sup> Edition Page No- 172-175.</strong></span></span></span></p>",
      "correct_choice_id": 60561,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15161,
      "choices": [
        {
          "id": 60604,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Physiological jaundice</span></p>"
        },
        {
          "id": 60605,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Breast milk jaundice</span></p>"
        },
        {
          "id": 60606,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Breastfeeding jaundice</span></p>"
        },
        {
          "id": 60607,
          "text": "<p><span style=\"font-size:11.0pt;\">Cholestatic jaundice</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A mother brings her 5-day-old baby, initially weighing 2.5 kg at birth, for a follow-up visit. The baby appears alert and active but presents with noticeable jaundice. The baby's weight has decreased to 2 kg, and the stool color is described as yellow. Considering the baby's age, weight loss, and clinical presentation, what is the most likely cause of the jaundice observed in this infant?</span></p>",
      "unique_key": "Q3103042",
      "question_audio": null,
      "question_video": null,
      "map_id": 32623,
      "difficulty_level": "difficult",
      "subjects_id": [
        13
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. C) Breastfeeding jaundice</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option C:&nbsp;</strong></span></p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Breastfeeding jaundice </strong>typically occurs <strong>within the first week of life </strong>and can be <strong>associated with inadequate breast milk intake</strong>, leading to <strong>dehydration and increased bilirubin levels </strong>due to <strong>reduced stool production </strong>and, consequently, <strong>less bilirubin excretion</strong>. The significant <strong>weight loss </strong>(from 2.5 kg to 2 kg) suggests <strong>inadequate feeding</strong>, which supports the <strong>diagnosis of breastfeeding jaundice</strong>. The <strong>baby being alert </strong>and <strong>active with yellow stools </strong>also aligns with this condition, as <strong>cholestasis </strong>typically presents with <strong>acholic </strong>(pale) <strong>stools </strong>and possibly more significant systemic symptoms.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option A:&nbsp;Physiological jaundice </strong>usually <strong>appears on the 2nd or 3rd day of life</strong>, <strong>peaking around </strong>the <strong>4th to 5th day</strong>, but it would not typically cause significant weight loss or be the sole reason for concern in an otherwise healthy infant.</span><br>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option B:&nbsp;Breast milk jaundice </strong>tends to <strong>appear later than breastfeeding jaundice</strong>, usually at the <strong>end of the first week </strong>into the <strong>second week of life </strong>and is associated with <strong>lipoprotein lipase enzyme </strong>in the <strong>mother's breast milk </strong>that can <strong>increase bilirubin levels</strong>. It wouldn't be the leading cause of jaundice in a 5-day-old infant, especially with significant weight loss.</span><br>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option D:&nbsp;Cholestatic jaundice</strong>, which results from <strong>impaired bile flow</strong>, would not typically present this early without other signs of liver dysfunction and would be associated with pale or acholic stools due to the lack of bile excretion. (increased conjugated bilirubin)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Exclusively breastfed infants have a different pattern of physiological jaundice as compared to artificially fed babies.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Jaundice in breastfed babies </strong>usually <strong>appears between 24-72 hr of age</strong>, <strong>peaks by 5-15 days of life </strong>and <strong>disappears </strong>by the <strong>third week of life</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>One-third of all breastfed babies </strong>are <strong>detected </strong>to <strong>have mild clinical jaundice </strong>in the <strong>third week of life</strong>, which may persist into the 2nd to 3rd month of life in a few babies. This increased frequency of jaundice in breastfed babies is not related to characteristics of breast milk but rather to inadequate breastfeeding (breastfeeding jaundice).</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Ensuring optimum breastfeeding would help decrease this kind of jaundice.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Ref</u></strong></span><span style=\"font-size:12pt;\"><strong>-</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>OP Ghai 8<sup>th</sup> Edition Page No- 172</strong></span></p>",
      "correct_choice_id": 60606,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15163,
      "choices": [
        {
          "id": 60612,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Photooxidation</span></span></span></p>"
        },
        {
          "id": 60613,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Photoisomerization</span></span></span></p>"
        },
        {
          "id": 60614,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Structural isomerization</span></span></span></p>"
        },
        {
          "id": 60615,
          "text": "<p><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conjugation</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A mother brings her newborn to the hospital for a procedure, as shown in the image. The child has a history of hyperbilirubinemia. The infant is placed under a type of light as part of the treatment. Which mechanism is chiefly responsible for the reduction in the levels of serum bilirubin during the procedure depicted?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/09/picture1_OVQZJf1.jpg\" style=\"height:173px; width:250px\" /></span></span></span></p>",
      "unique_key": "Q9581247",
      "question_audio": null,
      "question_video": null,
      "map_id": 32625,
      "difficulty_level": "intermediate",
      "subjects_id": [
        13
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Structural isomerization</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C: Structural isomerization</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The procedure shown here is <strong>Phototherapy for neonatal Jaundice</strong>, the main mechanism seen in this case is <strong>Structural isomerization of the unconjugated bilirubin </strong>into the <strong>Lumirubin</strong>, which is a <strong>water-soluble compound excreted by the kidneys</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Photooxidation:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is a <strong>minor reaction</strong>, where, <strong>photoproducts are excreted in urine</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Photoisomerization:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This term refers to the <strong>light-induced conversion </strong>of <strong>bilirubin </strong>to a <strong>different isomer</strong>, specifically <strong>converting the Z, Z-bilirubin </strong>to the <strong>more polar E,Z-bilirubin </strong>and <strong>E,E-bilirubin isomers</strong>. These isomers are more water-soluble and can be excreted without conjugation. It is </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">is one of the mechanisms by which the phototherapy acts whereas the main mechanism is <strong>Structural isomerization.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Conjugation:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Conjugation is a <strong>liver process </strong>where <strong>bilirubin is made water-soluble </strong>by <strong>adding a glucuronic acid molecule</strong>, allowing it to be <strong>excreted in bile</strong>. This is not the process used by phototherapy to reduce bilirubin; rather, it is the natural metabolic pathway that may be deficient in newborns, leading to hyperbilirubinemia.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Phototherapy remains the mainstay </strong>of <strong>treating hyperbilirubinemia in neonates. </strong>It acts by <strong>converting insoluble bilirubin </strong>(unconjugated) into <strong>soluble isomers </strong>that can be <strong>excreted in urine and feces</strong>. The <strong>bilirubin molecule isomerizes </strong>to <strong>harmless forms </strong>under <strong>blue-green light (460-490 nm). Structural isomerization </strong>is mainly responsible for <strong>phototherapy induced decline in TSB</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>-</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>OP Ghai 9<sup>th</sup> Edition Page No- 171.</strong></span></span></span></p>",
      "correct_choice_id": 60614,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}